Selected CD34+ cell autologous transplantation for advanced malignant tumors.
- Author:
Lu-jia DONG
1
;
Hu CHEN
;
Min JIANG
;
Liang-ding HU
;
Mao-quan QIN
;
Wei-jing ZHANG
;
Zhi-yong YU
;
Shi-kai WU
;
Xi-lin CHEN
;
Yun-hua BAO
;
San-tai SONG
;
Duan-qi LIU
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Antigens, CD34; analysis; Child; Female; Hematopoietic Stem Cell Transplantation; adverse effects; Humans; Male; Middle Aged; Neoplasms; mortality; therapy; Survival Rate; Transplantation, Autologous
- From: Chinese Journal of Oncology 2003;25(2):183-185
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo determine the clinical results of selected CD34(+) cell autologous transplantation in advanced malignant tumors.
METHODSAfter pretreatment, fifteen patients aged 12 - 70 (49.5) years with various Stage III or IV malignant tumors were given the sorted CD34(+) cells collected by magnetic-activated cell sorting (Clini MACS, Milteny Biotech, Germany).
RESULTSPeripheral blood progenitor cells (PBPC) from the patients were mobilized by chemotherapy and G-CSF 5 micro g/kg per day. CD34(+) cells gave 2.0 - 5 log depletion after cell sorting, with a median yield of CD34(+) selected cells of 2.4 (0.15 - 12.03) x 10(6)/kg. It gave a median recovery of 64 (52 - 81.4)% and median purity of 98.2 (83.2 - 99.7)%. The median time of neutrophil recovery > 1.0 x 10(9)/L and platelet recovery > 20 x 10(9)/L post-transplantation were 14 (8 - 26) days and 13 (11 - 35) days, respectively. On follow-up of 2 - 33 (11) months, the event-free survival rate was 53.3% (8/15) and the overall survival rate was 66.7% (10/15).
CONCLUSIONTransplantation of autologous selected PBPC CD34(+) cells gives prompt and stable engraftment. Selected CD34(+) cell transplantation, being a safe approach, may improve the clinical outcome even in patients with advanced malignant tumors.
